Dr. Papadimitrakopoulou Provides an Update on Pembrolizumab for Lung Cancer

Vassiliki Papadimitrakopoulou, MD
Published: Friday, Nov 07, 2014

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

Pembrolizumab is currently being studied in patients whose tumors express PD-L1. This is a smart enrichment strategy for treating patients, Papadimitrakopoulou says, and the activity seen so far could be because of this selection. However, all evidence so far points to good activity with this agent in all settings of non-small cell lung cancer.

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

Pembrolizumab is currently being studied in patients whose tumors express PD-L1. This is a smart enrichment strategy for treating patients, Papadimitrakopoulou says, and the activity seen so far could be because of this selection. However, all evidence so far points to good activity with this agent in all settings of non-small cell lung cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x